Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: Lenalidomide plus dexamethasone vs bortezomib

Journal of Medical Economics

Volumn 14, Issue 6, 2011, Pages 690-697

  Möller, Jörgen ^a   Nicklasson, Lars ^b   Murthy, Ananthram ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Celgene International   (Switzerland)

Author keywords

Costs; Discrete event simulation; Economic modeling; Effects; Incremental cost effectiveness ratio (ICER); Myeloma; Time to progression

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE;

ADULT; ADVERSE OUTCOME; ANEMIA; ARTICLE; CONSTIPATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; NORWAY; PATIENT CODING; PERIPHERAL NEUROPATHY; PNEUMONIA; PREDICTION; QUALITY OF LIFE; REFRACTORY PERIOD; REIMBURSEMENT; RELAPSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; MULTIPLE MYELOMA; NORWAY; PYRAZINES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; THALIDOMIDE;

EID: 81255165723     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.611841     Document Type: Article

References (35)

1. Mileshkin L, Prince HM. The adverse prognostic impact of advanced age in multiple myeloma. Leuk Lymphoma 2005;46:951-66 (Pubitemid 40975015)
2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60
3. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EMBT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23 (Pubitemid 28435189)
4. Agarwal JR, Matsui W. Multiple myeloma: A paradigm for translation of the cancer stem cell hypothesis. Anticancer Agents Med Chem 2010;10:116-20
5. Nordic Myeloma Study Group. Available at: http://www.nordic-myeloma.org/ content/no/ommyelomatose/default.asp. Accessed 16 May 2011
6. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111:2516-20
7. Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of autogolous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myé lome. N Engl J Med 1996;335:91-7 (Pubitemid 26240110)
8. Barlogie B, Jagannath S, Epstein J, et al. Biology and therapy of multiple myeloma in 1996. Semin Hematol 1997;34(1 Suppl):67-72
9. Messori A, Maratea D, Nozzoli C, et al. The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information. Pharmacoeconomics 2011;29:269-85
10. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147-52
11. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42 (Pubitemid 350146108)
12. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32 (Pubitemid 350146107)
13. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-60 (Pubitemid 350159621)
14. Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 2009;12:409-18
15. Ross JR, Saunders Y, Edmonds PM, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 2004;8:1-176
16. Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005;23:323-32 (Pubitemid 40677051)
17. Kelton WD, Sadowski RP, Sadowski DA. Simulation with ARENA. Boston: McGraw-Hill, 1998
18. Norwegian Medicines Agency. Available at: http://www.legemiddelverket.no/ templates/InterPage-25644.aspx?filterByCopyToGeneral#5.%20 Choice%20of%20basis%20for%20comparison. Accessed 2nd August 2011
19. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73 (Pubitemid 44264086)
20. Norwegian Medicines Agency. Available at: http://www.legemiddelverket.no/ [last accessed 16 May 2011]
21. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98 (Pubitemid 41007864)
22. Norwegian Medicines Agency. Available at: http://www.legemiddelverket.no/ templates/InterPage-82929.aspx. Accessed 12 May 2011
23. Informasjonshefte Innsattsstyrt finansiering, Helse-og omsorgsdepartementet 2006
24. van Agthoven M, Segeren CM, Buijt I, et al. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study. Eur J Cancer 2004;40:1159-69 (Pubitemid 38526334)
25. Birch S, Gafni A. Information created to avoid reality (ICER): things we should not look to for answers. Pharmacoeconomics 2006;24:1121-31 (Pubitemid 44683368)
26. Chabot I, Rocchi A. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. Value Health 2010;13:837-45
27. Ström O, Borgström F, Kleman M, et al. FRAX and its applications in health economics-cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 2010;47:430-43
28. Vossius C, Nilsen OB, Larsen JP. Health state values during the first year of drug treatment in early-stage Parkinson's disease: A prospective, populationbased, cohort study. Drugs Aging 2009;26:973-80
29. Bringedal B, Iversen T, Kristiansen IS. Hvor mye br samfunnet vre villig til a betale for helseforbedringer? Verdien av liv og helse. HERO Skriftserie 2003
30. Oslo: Universitetet i Oslo, 2003
31. Veileder isamfunnskonomiske analyser. Oslo: Finansdepartementet, 2005. (odin.dep.no/filarkiv/266324/Veileder i samfunnsok analyse (4.10. 2006).)
32. Tandvards och Lakemedelsformansverket. Dental and Pharmaceutical Benefts Agency, TLV, [online]. Available at: http://www.tlv.se/upload/beslut-2010/ bes100701-revlimid.pdf. Accessed 21 Mar 2011
33. Hornberger J, Rickert J, Dhawan R, et al. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. Eur J Haematol 2010;85:484-591
34. Ishak J, Rodrigues F. Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. Eur J Haematol 2011;87:95 (in response to Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Lö thgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. Eur J Haematol 2010;85:484-91)
35. Durie BG, Borello I, Binder G, et al. Treatment cost comparison in relapsed multiple myeloma. Haematologica 2011;96(1 Suppl):poster P-379